Association of miR-21 rs1292037 polymorphism with congenital heart disease susceptibility in Chinese children [0.03%]
miR-21 rs1292037多态性与中国儿童先天性心脏病易感性的关联分析
Hongjuan Tang,Wenjuan Zhang,Dan Xu et al.
Hongjuan Tang et al.
Background: Congenital heart disease (CHD) is a condition characterized by structural or functional abnormalities of the cardiovascular system present at birth. This study investigated the correlation between microRNA-21 ...
Tailoring pediatric vancomycin doses: achieving therapeutic levels and minimizing toxicity in oncology patients [0.03%]
儿科万古霉素剂量的调整：在肿瘤患者中达到治疗水平并最小化毒性
Nadeen Hossam,Dalia Makhlouf,Ahmed Elzeiny et al.
Nadeen Hossam et al.
Background: Vancomycin is a widely used nephrotoxic drug in pediatric oncology. Our aim was to assess the initial vancomycin dosing protocols required for achieving the target therapeutic concentrations of vancomycin betw...
Ready to test your DNA?: Public acceptance of genetic testing in the precision medicine era among Chinese residents [0.03%]
精准医疗时代我国居民基因检测的公众接受度调查：你准备好了吗？
Cong Pang,Qun Wang,Zhongxin Su et al.
Cong Pang et al.
Aim: This study aimed to explore the Chinese public's experiences with, perceptions of, attitudes toward, and willingness to use genetic testing (GT) in the precision medicine era. ...
Leveraging circulating microRNAs for personalized disease-modifying therapies in type 1 diabetes [0.03%]
利用循环microRNA进行1型糖尿病的个性化疾病修饰治疗
Giuseppina Emanuela Grieco,Francesco Dotta,Guido Sebastiani
Giuseppina Emanuela Grieco
Type 1 Diabetes (T1D) is a chronic autoimmune disease marked by the progressive immune-mediated destruction of insulin-producing pancreatic beta-cells. The clinical management of T1D is complicated by its heterogeneity and the variability i...
Navigating ethical problems of commercialization: towards inclusive organoid research [0.03%]
导航商业化伦理问题：迈向包容性类器官研究
Manon van Daal,Karin R Jongsma
Manon van Daal
Organoids are three-dimensional, self-organizing cell structures grown from human biospecimens that allow researchers to study development, disease, and drug responses. Organoid technology holds promise for precision medicine, as it can tai...
Val66Met polymorphism in the BDNF gene and antidepressant response in depression: an updated meta-analysis [0.03%]
抑郁症中BDNF基因Val66Met多态性与抗抑郁药疗效的meta分析更新研究
Raphael Enrique Tiongco,Roselle Arbas,Ana Caguiat et al.
Raphael Enrique Tiongco et al.
Introduction: The Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene has been linked to antidepressant treatment response in patients with major depressive disorder (MDD), yet findings remain incon...
Awareness, and interest in personalized medicine: a cross-sectional survey study of health professionals [0.03%]
一项健康专业人员的横断面调查研究：对个性化医疗的认识和兴趣
Ali Mostafaei,Aysan Rahmani,Kavous Shahsavarinia et al.
Ali Mostafaei et al.
Background: Personalized medicine (PM) is advancing disease prevention and treatment, but regulatory and clinical concerns persist, requiring evaluation of healthcare professionals' (HPs) knowledge and attitudes. ...
A rare likely pathogenic HLA-DRB1 variant with compromised immunity in severe COVID-19 patient and in-hospital mortality [0.03%]
一个罕见的致病性HLA-DRB1变异体与重症COVID-19患者的免疫功能受损和住院死亡率有关
Rashid Mir,Badr A Alsayed,Mohammad Fahad Ullah
Rashid Mir
The severity of COVID-19 disease can vary greatly, influenced by genetic factors and comorbid conditions that may increase mortality. This study has examined potential genetic influences on the disease for a young adult aged 36 years with T...
A scoping review of the cost-effectiveness of precision treatment in chronic lymphocytic leukemia [0.03%]
慢性淋巴细胞白血病精准治疗的成本效益的综述性研究
Jesman Punian,Morgan Ehman,Deirdre Weymann et al.
Jesman Punian et al.
Chronic lymphocytic leukemia (CLL) is a common, incurable leukemia. Precision treatment for CLL uses genetic testing to align therapeutic selection with patient characteristics. Insurers are uneven in their reimbursement of precision CLL tr...
Optimizing breast cancer therapy: chemoressitance and machine learning for precision prediction [0.03%]
优化乳腺癌治疗：利用化疗和机器学习实现精准预测
Martina Lichtenfels,Matheus G S Dalmolin,Julia Caroline Marcolin et al.
Martina Lichtenfels et al.
Background: Validate a novel in vitro resistance platform for breast cancer (BC) by assessing resistance profiles of treatment-naïve and residual tumors after neoadjuvant chemotherapy (NACT) and applying a machine learni...